Literature DB >> 1457348

Oestrogen receptor isoforms, their distribution and relation to progesterone receptor levels in breast cancer samples.

V A Baker1, J R Puddefoot, S Marsigliante, S Barker, A W Goode, G P Vinson.   

Abstract

Oestrogen receptors (ER) in breast cancer tumours are highly heterogeneous. In this study, the variability in the profile of ER isoforms and its relation to progesterone receptor (PgR) levels in breast tumours has been studied. Using high resolution isoelectric focusing (IEF) 4 ER isoforms can be detected with pI values of 6.1 (corresponding to the 8S ER), and 6.3, 6.6 and 6.8 (all of which have a sedimentation pI values of 6.1 (corresponding to the 8S ER), and 6.3, 6.6 and 6.8 (all of which have a sedimentation coefficient of approximately 4S in sucrose density gradients). Data were obtained on the soluble receptors from supernatants of 66 ER-positive primary breast tumour homogenates using high resolution IEF. In 43 of these samples PgR levels were also measured. The isoform at pI 6.6 was present in 97.0% of tumours, the isoform at pI 6.1 in 83.3%, the pI 6.3 isoform 39.4% of tumours and the pI 6.8 isoform in only 33.3% of tumours. Only 12.1% of tumours studied contained the full complement of ER isoforms (pI 6.1, 6.3, 6.6 &amp; 6.8). The ER isoforms at pI 6.1 &amp; 6.8 were only found in PgR-positive (> 10 fmol PgR/mg protein) tumours. Some tumours contained only a single ER isoform at pI 6.6 or 6.1, but those at pI 6.3 and 6.8 were never found singly. Tumours containing 3 or 4 ER isoforms had significantly higher levels of PgR (> 90 fmol/mg protein) than those with only 1 or 2 (P < 0.001). The presence of ER isoforms at pI 6.3 and pI 6.8 also significantly correlated with high levels of PgR (P < 0.001). This variability in the ER isoform profile of breast tumours and their correlation with PgR levels may have a bearing on prognosis and tumour response to endocrine therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457348      PMCID: PMC1978007          DOI: 10.1038/bjc.1992.414

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

Review 1.  Estrogen receptor variants in human breast cancer.

Authors:  L C Murphy
Journal:  Mol Cell Endocrinol       Date:  1990-12-03       Impact factor: 4.102

2.  Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines.

Authors:  F E May; M D Johnson; L R Wiseman; A E Wakeling; P Kastner; B R Westley
Journal:  J Steroid Biochem       Date:  1989-12       Impact factor: 4.292

3.  Identification of a variant form of the human estrogen receptor with an amino acid replacement.

Authors:  T Garcia; M Sanchez; J L Cox; P A Shaw; J B Ross; S Lehrer; B Schachter
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

4.  Mechanisms regulating the concentration and the conformation of progesterone receptor(s) in the uterus.

Authors:  E Milgrom; L Thi; M Atger; E E Baulieu
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

5.  Discrepancies between antibody (EIA) and saturation analysis of oestrogen receptor content in breast tumour samples.

Authors:  S Marsigliante; J R Puddefoot; S Barker; J Gledhill; G P Vinson
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-10       Impact factor: 4.292

6.  Progestin inhibition of progesterone receptor gene expression in human breast cancer cells.

Authors:  I E Alexander; C L Clarke; J Shine; R L Sutherland
Journal:  Mol Endocrinol       Date:  1989-09

7.  Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples.

Authors:  L C Murphy; H Dotzlaw
Journal:  Mol Endocrinol       Date:  1989-04

8.  4 S oestrogen receptor isoforms and their distribution in breast cancer samples.

Authors:  S Marsigliante; V A Baker; J Puddefoot; S Barker; G P Vinson
Journal:  J Mol Endocrinol       Date:  1991-12       Impact factor: 5.098

9.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

Authors:  S A Fuqua; S D Fitzgerald; G C Chamness; A K Tandon; D P McDonnell; Z Nawaz; B W O'Malley; W L McGuire
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

10.  A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors.

Authors:  T Garcia; S Lehrer; W D Bloomer; B Schachter
Journal:  Mol Endocrinol       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.